Exelixis, Inc. (NASDAQ:EXEL) was the recipient of some unusual options trading on Monday. Stock traders acquired 7,218 call options on the stock. This is an increase of 585% compared to the average daily volume of 1,054 call options.
A number of institutional investors have recently modified their holdings of EXEL. Vanguard Group Inc. lifted its stake in shares of Exelixis by 7.2% during the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock worth $626,635,000 after purchasing an additional 1,706,893 shares in the last quarter. Matrix Capital Management Company LP lifted its stake in shares of Exelixis by 8.8% during the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after purchasing an additional 1,225,000 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Exelixis during the second quarter worth about $28,689,000. Macquarie Group Ltd. lifted its stake in shares of Exelixis by 811.5% during the third quarter. Macquarie Group Ltd. now owns 1,276,453 shares of the biotechnology company’s stock worth $30,928,000 after purchasing an additional 1,136,409 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of Exelixis by 588.9% during the third quarter. First Trust Advisors LP now owns 1,086,135 shares of the biotechnology company’s stock worth $26,317,000 after purchasing an additional 928,475 shares in the last quarter. Hedge funds and other institutional investors own 81.15% of the company’s stock.
Several equities analysts recently weighed in on the company. Cann reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Leerink Swann downgraded Exelixis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $34.00 to $28.00 in a research note on Friday, September 22nd. Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. SunTrust Banks raised their price target on Exelixis from $32.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $26.00 price target on shares of Exelixis in a research report on Tuesday, October 17th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Exelixis has an average rating of “Buy” and an average target price of $31.75.
Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The firm had revenue of $152.50 million for the quarter, compared to analysts’ expectations of $104.91 million. During the same quarter last year, the firm earned ($0.04) earnings per share. The firm’s revenue for the quarter was up 145.2% compared to the same quarter last year. research analysts forecast that Exelixis will post 0.49 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/28/traders-purchase-high-volume-of-exelixis-call-options-exel.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
What are top analysts saying about Exelixis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exelixis and related companies.